Inclusion Body Myositis Market By Product and Service (Rehabilitation Services, Mobility and Adaptive Equipment, Diagnostic Services, Pharmacological Therapies, Dysphagia Management Products and Procedures, Home Healthcare Services, Skilled Nursing and Long-Term Care Services); By Application (Muscle Strength and Mobility Management, Fall Prevention and Balance Support, Dysphagia and Aspiration Management, Diagnostic Evaluation and Disease Monitoring, Daily-Living and Functional Support, Clinical Trial and Investigational Treatment Management); By End User (Hospitals, Specialty Neuromuscular and Myositis Centers, Rehabilitation Centers, Home Healthcare Providers, Diagnostic Laboratories, Skilled Nursing and Long-Term Care Facilities, Academic and Clinical Research Institutes); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Inclusion Body Myositis Market: Progressive Disability Sustains Supportive-Care Revenue as Drug Developers Target Earlier Disease

The Global Inclusion Body Myositis Market will register moderate expansion at a CAGR of 5.6%, rising from USD 1.50 billion in 2025 to USD 2.20 billion by 2032, according to Strategic Market Research.

 

Market revenue is generated across diagnostic services, rehabilitation, mobility and adaptive equipment, dysphagia management, hospital procedures, home healthcare, skilled nursing, and off-label pharmacotherapy. No medicine is currently approved specifically for inclusion body myositis, making long-term functional support and complication management the primary sources of spending.

 

IBM generally appears after age 50 and progressively weakens the finger flexors and quadriceps. Patients may struggle to grip objects, open containers, rise from chairs, climb stairs, or prevent sudden knee collapse. The disease can also impair swallowing, balance, and independent living. These losses create recurring expenditure over several years rather than a single treatment episode.

 

A successful disease-modifying therapy would add an orphan-drug category to a care pathway already divided among neuromuscular centers, rehabilitation providers, hospitals, infusion facilities, equipment suppliers, and home-care organizations. Commercial value will therefore depend on both treatment innovation and the continuing demand created by irreversible functional decline.

 

Functional Decline, Not Patient Volume, Determines Market Value

IBM affects a limited patient population, but its commercial burden rises sharply after diagnosis. A Medicare study comparing 361 older IBM patients with 1,805 matched beneficiaries found average annual healthcare expenditure of USD 44,838 for IBM patients, compared with USD 10,182 for controls. IBM was therefore associated with an incremental annual cost of USD 34,656 per patient. Inpatient expenditure alone averaged USD 18,639, almost seven times the USD 2,701 recorded for matched beneficiaries.

Expenditure extends beyond hospital admission. The same Medicare analysis reported average annual durable-medical-equipment costs of USD 2,361 for an IBM patient, compared with USD 239 for a matched beneficiary. Skilled-nursing expenditure averaged USD 6,148 versus USD 684, while home-health-agency expenditure reached USD 2,875 versus USD 391. Progressive weakness therefore shifts revenue from periodic neurological consultations toward mobility devices, transfer assistance, nursing support, and residential care.

Hospitals and specialty neuromuscular centers accounted for an estimated 43.5 share of the market in 2025, representing approximately USD 653 million, and are projected to expand at a CAGR of 5.1% through 2032. These facilities control muscle biopsy, electromyography, swallowing procedures, infusion attempts, inpatient complication management, and clinical-trial enrolment. Their position is reinforced by the number of specialties involved before IBM is confirmed.

Home healthcare represented an estimated 16.8 share, equivalent to approximately USD 252 million in 2025, and is forecast to grow at a CAGR of 7.8%. This faster expansion reflects increasing assistance requirements for bathing, dressing, transfers, meal preparation, medication use, fall recovery, feeding, and aspiration monitoring. Demand accelerates when informal caregivers can no longer provide continuous or physically demanding support.

Late diagnosis further increases expenditure. A U.S. claims analysis covering 2,435 diagnosed IBM patients found a median interval of 4.4 years between the first recorded IBM-related symptom and diagnosis. Approximately 30 of every 100 patients experienced a delay longer than six years. During the year before diagnosis, 84 of every 100 patients used office-based outpatient care, 62 used hospital outpatient services, 30 visited an emergency department, and 20 required inpatient treatment.

The prolonged diagnostic pathway reflects overlap with polymyositis, peripheral neuropathy, motor neuron disease, myasthenia gravis, orthopedic disorders, and age-associated weakness. Misclassification may lead to repeated corticosteroid or immunosuppressive treatment before IBM is confirmed. Earlier referral to a neuromuscular specialist can redirect spending toward appropriate rehabilitation, fall prevention, swallowing surveillance, mobility planning, and clinical-trial assessment.

 

Dual Inflammatory and Degenerative Injury Restricts Drug Response

IBM combines immune-mediated muscle injury with progressive cellular degeneration. Cytotoxic immune cells infiltrate muscle tissue, while damaged fibres accumulate abnormal proteins in rimmed vacuoles. Suppressing inflammation alone may therefore fail to restore muscle already affected by protein aggregation, mitochondrial dysfunction, impaired autophagy, or irreversible fibre loss. This mixed pathology helps explain why medicines used successfully in other inflammatory myopathies have produced limited or inconsistent IBM outcomes.

Sporadic IBM must also be separated from hereditary inclusion body myopathies. Sporadic IBM is an acquired inflammatory and degenerative condition that usually appears later in life. Hereditary inclusion body myopathies arise from genetic abnormalities, may begin earlier, and do not follow the same inflammatory pathway. Combining these groups would overstate the addressable population for an IBM-specific medicine and weaken clinical-trial design.

Drug developers are consequently examining several biological mechanisms rather than treating IBM as a conventional autoimmune disorder. Current and previous programs have targeted cytotoxic T cells, JAK-STAT signalling, mTOR activity, autophagy, protein homeostasis, mitochondrial function, and metabolic dysfunction.

 

Eight Management Pathways Define Current IBM Spending

Current IBM management is concentrated in eight recurring strategies divided across rehabilitation, off-label medication attempts, and swallowing intervention.

Physical therapy uses carefully controlled exercise, balance work, stretching, and transfer training to preserve remaining leg and core function without excessive muscle stress. Occupational therapy addresses finger-flexor weakness through grip adaptations, dressing and eating aids, home modifications, and mobility-equipment configuration. Speech-language therapy evaluates swallowing and teaches compensatory techniques intended to reduce choking and aspiration risk.

Medication attempts include corticosteroids such as prednisone, immunosuppressants such as methotrexate or azathioprine, and intravenous immunoglobulin. Corticosteroids and systemic immunosuppressants commonly fail to produce sustained functional improvement in IBM. IVIG may be attempted in selected patients, particularly when swallowing impairment is prominent, but it has not demonstrated consistent disease-modifying activity.

Localized swallowing interventions include botulinum toxin injection into the upper oesophageal sphincter and procedural treatment such as cricopharyngeal myotomy or oesophageal balloon dilation. These procedures are reserved for patients whose swallowing dysfunction is linked to impaired sphincter opening and who retain sufficient pharyngeal propulsion to benefit.

Rehabilitation, mobility, and adaptive equipment represented the largest product and service category in 2025, accounting for an estimated 46.8 share and approximately USD 702 million in revenue. The segment is projected to expand at a CAGR of 4.7% through 2032 as patients progress from recurring physical and occupational therapy to walkers, orthoses, transfer aids, powered wheelchairs, bathroom equipment, grip adaptations, and home-access systems.

A German IBM registry study found that 63.4 of every 100 patients received physiotherapy and 46.3 received occupational therapy. These utilization rates demonstrate why rehabilitation remains an established recurring revenue category despite the absence of an approved medicine. Growth is steady rather than rapid because therapy demand rises with disability, while major equipment categories have longer replacement cycles.

 

Dysphagia Converts IBM into a High-Risk Hospital Pathway

Swallowing dysfunction is one of the most commercially important IBM complications because it connects outpatient monitoring with imaging, nutrition, pulmonary care, emergency treatment, and interventional procedures. In a study of 57 IBM patients, 65 of every 100 reported dysphagia symptoms. Only 46 of every 100 had spontaneously raised the problem with a clinician, indicating that routine consultations can substantially under-identify swallowing impairment. Among patients undergoing videofluoroscopy, 79 of every 100 demonstrated swallowing abnormalities.

Dysphagia management accounted for an estimated 17.4 share of the IBM market in 2025, generating approximately USD 261 million, and is forecast to expand at a CAGR of 7.2% through 2032. Revenue includes speech-language therapy, videofluoroscopic studies, endoscopic assessment, aspiration surveillance, nutritional support, botulinum toxin treatment, oesophageal dilation, cricopharyngeal myotomy, and gastrostomy-related care.

Dysphagia may cause choking, dehydration, weight loss, aspiration, and recurrent respiratory infection. A U.S. inpatient analysis found that IBM patients had approximately three times the odds of aspiration pneumonia and 2.91 times the odds of gastrostomy placement compared with patients without IBM. They also had 2.05 times the odds of experiencing a fall. These IBM-specific outcomes support recurring demand for swallowing studies, speech-language therapy, aspiration monitoring, nutritional assessment, mobility intervention, and inpatient care.

Botulinum toxin, balloon dilation, and cricopharyngeal myotomy can improve swallowing in selected patients, but results depend on the underlying mechanism of dysfunction and may be temporary. The limited candidate pool prevents these procedures from dominating total market volume. Their higher revenue per intervention nevertheless makes dysphagia management one of the market’s fastest-growing application categories.

 

Ulviprubart Resets Development Around Preserved Function

Ulviprubart, previously called ABC008, is an investigational monoclonal antibody developed by Abcuro to selectively deplete KLRG1-positive cytotoxic T cells implicated in IBM muscle injury. The global Phase 2/3 MUSCLE study randomized 272 patients to low-dose ulviprubart, high-dose ulviprubart, or placebo and followed them for 76 weeks.

The trial did not meet its primary endpoint or key secondary endpoints. IBM Functional Rating Scale scores declined by 1.7 points in the low-dose group, 2.1 points in the high-dose group, and 2.4 points with placebo. The numerical difference for the low dose did not achieve statistical significance.

A prespecified subgroup with baseline IBM Functional Rating Scale scores of at least 29 declined by 1.3 points with either ulviprubart dose and 2.6 points with placebo. This represented a numerical slowing of approximately one-half in patients with less-severe disease, but the subgroup result also failed to reach statistical significance. Ulviprubart maintained a comparatively favourable safety and tolerability profile.

The result changes IBM development strategy in two ways. Future trials may favour patients who retain sufficient function for preservation to be measurable, while diagnostic companies and specialist centers gain greater importance in identifying patients before extensive quadriceps, hand, or swallowing impairment develops. Abcuro must now determine whether subgroup evidence justifies another targeted study, a partnership, or discontinuation of the IBM program.

 

Sirolimus Tests a Lower-Cost Disease-Modifying Model

Sirolimus, also known as rapamycin, combines immune-modulating activity with effects on mTOR signalling and autophagy. These mechanisms make it commercially relevant to IBM because it could address both cytotoxic immune activity and impaired cellular protein clearance.

The international OPTIMISM study is evaluating sirolimus against placebo in approximately 140 IBM patients. Participants are being assessed through Week 84, with change in the IBM Functional Rating Scale serving as the principal efficacy measure. The study is active but no longer recruiting, and its estimated primary completion is December 2027.

Sirolimus has an established manufacturing and clinical-use history, reducing some development risk compared with a new biologic. Generic availability and known safety limitations could restrict orphan-drug pricing. Positive results would nevertheless create a potentially lower-cost treatment option and place pressure on future biologics to demonstrate substantially better functional preservation.

 

JAK Inhibition Opens a Parallel Clinical Pathway

The BIGTIM study is assessing ruxolitinib in a randomized Phase 2/3 IBM program sponsored by Assistance Publique–Hôpitaux de Paris. The trial is based on evidence that interferon-gamma signalling through the JAK-STAT pathway contributes to inflammatory muscle injury. Unlike ulviprubart’s selective cytotoxic-cell approach, ruxolitinib attempts to interrupt intracellular inflammatory signalling. The study is recruiting, making it one of the most strategically relevant active IBM programs.

Earlier programs continue to inform pipeline selection. Arimoclomol did not establish clinical benefit but generated evidence around cellular stress and protein-homeostasis targets. Pioglitazone remains an exploratory metabolic approach rather than a validated IBM treatment. These outcomes are pushing developers toward biomarker-defined enrolment and earlier-stage disease rather than broad recruitment across all levels of disability.

 

Clinical Proof and Care-Pathway Control Define Competitive Advantage

IBM competition is divided between pharmaceutical developers seeking the first effective disease-modifying therapy and healthcare networks controlling diagnosis, rehabilitation, swallowing management, and complication treatment.

Abcuro possesses the largest completed IBM-specific biologic dataset through the 272-patient MUSCLE study. Its position is weakened by failure to meet the overall efficacy endpoint but preserved by safety findings and the numerical result in less-severe patients. The OPTIMISM academic consortium is testing whether sirolimus can create a repurposed, lower-cost treatment pathway, while Assistance Publique–Hôpitaux de Paris is advancing ruxolitinib through the BIGTIM program. Competition is therefore occurring across selective immune-cell depletion, mTOR modulation, autophagy, and JAK inhibition rather than through multiple drugs targeting the same mechanism.

Provider competition is shaped by specialist expertise and control of the patient pathway. Johns Hopkins offers dedicated myositis expertise and IBM-focused clinical assessment, while Mayo Clinic’s Neuromuscular Disease Group provides coordinated diagnostic evaluation for inclusion body myositis and related disorders. Centers combining neurology, rheumatology, pathology, rehabilitation, swallowing assessment, and trial access can retain a larger proportion of each patient’s lifetime expenditure than providers offering isolated consultations.

Hospital for Special Surgery and large healthcare networks such as Apollo Hospitals participate through rheumatology, neurology, rehabilitation, and multidisciplinary-care capacity. Their commercial opportunity is strongest where they establish IBM-specific referral protocols rather than treating patients solely within broad myositis or general muscle-disease programs.

North America accounted for an estimated 44.2 share of global IBM market revenue in 2025, equivalent to approximately USD 663 million, and is projected to expand at a CAGR of 5.3%. Its leadership reflects established neuromuscular centers, Medicare expenditure, rehabilitation access, clinical-trial infrastructure, and stronger availability of advanced mobility and swallowing services.

Asia-Pacific represented an estimated 20.1 share, generating approximately USD 302 million in 2025, and is expected to record a CAGR of 7.4% through 2032. Growth is supported by improving neurological referral networks, expanding private hospital capacity, wider rehabilitation access, and increasing IBM recognition among ageing populations in Japan, Australia, China, South Korea, and India.

Competitive advantage for a pharmaceutical company will depend on demonstrating preserved everyday function rather than simply changing an inflammatory biomarker. Trials must show that treatment slows deterioration in walking, transfers, hand use, swallowing, or other IBM Functional Rating Scale domains. Safety is especially important because the treatment population is older and may have cardiovascular, metabolic, infectious, or mobility-related comorbidities.

Providers and trial networks will differentiate through shorter diagnosis times, access to biopsy interpretation, standardized functional assessment, dysphagia surveillance, and identification of patients with sufficient remaining function for clinical trials. Equipment and home-care suppliers will compete through progressive product pathways that allow patients to move from basic walking support to powered mobility and transfer assistance without changing vendors.

 

Market Outlook: Approved Therapy Would Add Revenue Rather Than Replace Supportive Care

Rehabilitation, mobility assistance, swallowing management, home healthcare, skilled nursing, and hospital complication treatment will continue to generate most IBM revenue during the forecast period. The largest category, rehabilitation and adaptive equipment, is projected to retain its leadership despite expanding at a lower CAGR than dysphagia management and home healthcare because it is required across multiple stages of functional decline.

A first approved medicine would create a concentrated prescription category, but it would not eliminate supportive-care expenditure. Patients diagnosed after substantial muscle damage would still require physical therapy, occupational adaptations, mobility devices, swallowing management, and home assistance. Drug revenue would therefore be added to the existing care pathway rather than replacing it.

The most valuable treatment opportunity lies in patients with mild-to-moderate disease who retain measurable walking, hand, and swallowing function. Ulviprubart’s subgroup findings, the long-duration sirolimus trial, and the recruiting ruxolitinib program all reinforce the commercial importance of earlier diagnosis and functional stratification.

IBM market growth will consequently follow a defined mechanism: earlier specialist recognition expands the diagnosed population; functional monitoring identifies patients before irreversible decline; supportive services generate recurring revenue; and a therapy that proves sustained functional preservation can establish a premium orphan-drug category alongside, rather than instead of, long-term rehabilitation and care.

 

Inclusion Body Myositis Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 1.50 Billion
Revenue Forecast in 2032	USD 2.20 Billion
Overall Growth Rate	CAGR of 5.6% (2026 – 2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million, CAGR (2026 – 2032)
Segmentation	By Product and Service, By Application, By End User, By Geography
By Product and Service	Rehabilitation Services, Mobility and Adaptive Equipment, Diagnostic Services, Pharmacological Therapies, Dysphagia Management Products and Procedures, Home Healthcare Services, Skilled Nursing and Long-Term Care Services
By Application	Muscle Strength and Mobility Management, Fall Prevention and Balance Support, Dysphagia and Aspiration Management, Diagnostic Evaluation and Disease Monitoring, Daily-Living and Functional Support, Clinical Trial and Investigational Treatment Management
By End User	Hospitals, Specialty Neuromuscular and Myositis Centers, Rehabilitation Centers, Home Healthcare Providers, Diagnostic Laboratories, Skilled Nursing and Long-Term Care Facilities, Academic and Clinical Research Institutes
By Region	North America, Europe, Asia-Pacific, Latin America, Middle East and Africa
Country Scope	U.S., Canada, UK, Germany, France, Italy, Spain, Japan, China, India, South Korea, Australia, Brazil, Mexico, GCC Countries, South Africa
Market Drivers	Increasing focus on chronic neuromuscular disease management, rising demand for supportive rehabilitation and mobility solutions, growing adoption of advanced diagnostics and personalized treatment approaches
Customization Option	Available upon request